← Back to Analyst Consensus 
TAK Buy
TAKEDA PHARMACEUTICAL CO LTD
Current Price —
Implied Upside —
Analysts 21
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| May 16, 2023 | TD Cowen | maintain | Outperform → Outperform | $20 | 54% |
| Apr 4, 2023 | TD Cowen | maintain | — → Outperform | $30 | 54% |
| Mar 16, 2023 | B of A Securities | upgrade | Neutral → Buy | $20 | 53% |
| Jul 19, 2022 | Cowen & Co. | upgrade | Market Perform → Outperform | $24 | — |
| Oct 7, 2021 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $0 | 54% |
| Mar 11, 2020 | JP Morgan | maintain | — → Overweight | $30 | 55% |
| Nov 1, 2019 | Cowen & Co. | initiate | — → Market Perform | $19.5 | — |
| Sep 24, 2019 | Jefferies | initiate | — → Buy | $0 | 52% |
Price Target Trend
Jul 4, 2026 Oct 26, 2026
EPS Estimates
+1y —
0q —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days